• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Jesper Ericsson appointed new CEO of Symcel

Jesper Ericsson appointed new CEO of Symcel

September 1, 2017
CenterWatch Staff

Symcel has announced that Jesper Ericsson has joined Symcel as Chief Executive Officer—with the appointment effective immediately. Ericsson was formally Director of Marketing and Sales at BioLamina, where he was responsible for direct sales both internationally and at a global and regional distributor level. During the past 10 years, Jesper has gained broad experience of the commercialization of research-based products through his work at the Unit for Bioentrepreneurship at the Karolinska Institute, Stockholm School of Entrepreneurship and as co-founder of the Stockholm BiotechBuilders Association. He holds a Ph.D. in neuroscience from the Karolinska Institute and a MSc in medical technology from the Royal Institute of Technology in Stockholm.

Jesper Ericsson commented, “I very much look forward to developing the plan and globally establishing Symcel's solutions for phenotypic screening—with a substantial focus on sales and marketing in the coming years.”

“Jesper’s experience in selling and marketing products towards the research market will strengthen Symcel's sales within different segments, especially for microbiology applications,” remarked Björn Varnestig, Chairman of Symcel.

“The Board wishes to thank Christer Wallin for his strong commitment and contribution over the past six years. During this time, the company's product CalScreener has been successfully developed and launched on the market. Christer has industrialized production processes and increased quality assurance,” Björn Varnestig added.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing